Skip to main content

Advertisement

SpringerLink
Log in

Phase II open-label study of sunitinib in patients with advanced breast cancer

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

This multicenter, open-label phase II study was conducted to evaluate sunitinib monotherapy in patients with either metastatic or locoregionally recurrent advanced breast cancer. Patients received sunitinib 37.5 mg on a continuous daily dosing schedule. The primary endpoint was objective response rate (ORR); the predefined target ORR was 25 %. All 83 patients enrolled into the study received study treatment. The majority of patients (90 %) had metastatic disease; 92 % had received prior systemic therapies, and 60 % had received two or more regimens for early and/or advanced disease. The ORR was 8 % (95 % exact CI, 4–17), comprising seven partial responses. In patients with superficial lesions (defined as cutaneous or palpable chest wall lesions), the ORR was 20 % (three of 15 evaluable patients), which was higher than that in patients with non-superficial disease (9 %; six of 64 patients). Median progression-free survival in the overall population was 3.6 months (95 % CI, 2.4–3.9); median overall survival was 15.6 months (95 % CI, 14.0–22.7). No new or unexpected safety findings were reported. The most commonly reported adverse events (AEs) were fatigue (60 %), diarrhea (54 %), and nausea (49 %). The most commonly reported grade 3/4 AEs were fatigue (17 %), neutropenia (16 %), and thrombocytopenia (11 %). Four patients (5 %) had a dose reduction due to an AE, and 39 patients (47 %) had temporary discontinuations of therapy due to AEs. Two on-study deaths were reported, one due to a pulmonary embolism (considered related to treatment) and one attributed to dyspnea and a myocardial infarction (considered unrelated to treatment). Patient-reported outcomes suggested that sunitinib treatment did not have a negative impact overall on patients’ functional domains or the majority of symptom scales. The trial did not meet its prespecified primary endpoint, and in view of the negative results obtained in several other trials, sunitinib will not be developed further for this indication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Althuis MD, Dozier JD, Anderson WF, Devesa SS, Brinton LA (2005) Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol 34(2):405–412. doi:10.1093/ije/dyh414

    Article  PubMed  Google Scholar 

  2. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4(9):536–550. doi:10.1038/ncponc0905

    Article  PubMed  CAS  Google Scholar 

  3. Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirström K, Ostman A (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175(1):334–341. doi:10.2353/ajpath.2009.081030

    Article  PubMed  Google Scholar 

  4. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337

    PubMed  CAS  Google Scholar 

  5. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2(5):471–478

    PubMed  CAS  Google Scholar 

  6. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O’Farrell AM, Cherrington JM, Pryer NK (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20(8):757–766. doi:10.1023/B:CLIN.0000006873.65590.68

    Article  PubMed  CAS  Google Scholar 

  7. Kodera Y, Katanasaka Y, Kitamura Y, Hitoshi T, Nishio K, Tamura T, Koizumi F (2011) Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 13(3):R66. doi:10.1186/bcr2903

    Article  PubMed  CAS  Google Scholar 

  8. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26(11):1810–1816. doi:10.1200/JCO.2007.14.5375

    Article  PubMed  CAS  Google Scholar 

  9. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27(25):4068–4075. doi:10.1200/JCO.2008.20.5476

    Article  PubMed  CAS  Google Scholar 

  10. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2012) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118(5):1252–1259. doi:10.1002/cncr.26440

    Article  PubMed  CAS  Google Scholar 

  11. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45(11):1959–1968. doi:10.1016/j.ejca.2009.02.011

    Article  PubMed  CAS  Google Scholar 

  12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to valuate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216. doi:10.1093/jnci/92.3.205

    Article  PubMed  CAS  Google Scholar 

  13. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144

    PubMed  CAS  Google Scholar 

  14. Carlson GW, Styblo TM, Lyles RH, Bostwick J, Murray DR, Staley CA, Wood WC (2003) Local recurrence after skin-sparing mastectomy: tumor biology or surgical conservatism? Ann Surg Oncol 10(5):575–581. doi:10.1245/ASO.2003.03.053

    Article  PubMed  Google Scholar 

  15. Haffty BG, Buchholz TA (2010) Molecular predictors of locoregional recurrence in breast cancer: Ready for prime time? J Clin Oncol 28(10):1627–1629. doi:10.1200/JCO.2009.27.1080

    Article  PubMed  Google Scholar 

  16. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(20):3271–3277. doi:10.1200/JCO.2009.24.9284

    Article  PubMed  Google Scholar 

  17. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28(10):1677–1683. doi:10.1200/JCO.2009.23.7610

    Article  PubMed  Google Scholar 

  18. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29(29):3885–3891. doi:10.1200/JCO.2011.36.1105

    Article  PubMed  Google Scholar 

  19. Curigliano G, Pivot X, Cortes J, Elias A, Cesari R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A (2010) A randomized phase II study of sunitinib vs standard of care for patients with previously treated advanced triple-negative breast cancer. Presented at the 33rd San Antonio Breast Cancer Symposium, 8–12 December, 2010 (poster presentation; abstract P6-12-02)

  20. Barrios CH, Liu M-C, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121(1):121–131. doi:10.1158/0008-5472

    Article  PubMed  CAS  Google Scholar 

  21. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(Suppl 16):117–124. doi:10.1053/j.seminoncol.2003.08.013

    Article  PubMed  CAS  Google Scholar 

  22. Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA (2009) Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 27(1):11–15. doi:10.1200/JCO.2007.15.5242

    Article  PubMed  CAS  Google Scholar 

  23. Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L, Gianni L (2009) Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 20(7):616–624. doi:10.1097/CAD.0b013e32832b2ea0

    Article  PubMed  CAS  Google Scholar 

  24. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11(2):82–92. doi:10.1016/j.clbc.2011.03.005

    Article  PubMed  CAS  Google Scholar 

  25. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30(9):921–929. doi:10.1200/JCO.2011.35.7376

    Article  PubMed  CAS  Google Scholar 

  26. Crown J, Dieras V, Staroslawska E, Yardley DA, Davidson N, Bachelot TD, Tassell VR, Huang X, Kern KA, Romieu G (2010) Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer. J Clin Oncol 28(Suppl 18):Abstract LBA1011

  27. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676. doi:10.1056/NEJMoa072113

    Article  PubMed  CAS  Google Scholar 

  28. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan S, Zhou X, Phan S-C, O’Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260. doi:10.1200/JCO.2010.28.0982

    Article  PubMed  CAS  Google Scholar 

  29. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247. doi:10.1200/JCO.2008.21.6457

    Article  PubMed  CAS  Google Scholar 

  30. Miller KD, Chap LI, Homes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792–799. doi:10.1200/JCO.2005.05.098

    Article  PubMed  CAS  Google Scholar 

  31. O’Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, Cortes J, Zhou X, Phan S, Miller K (2010) A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28(Suppl 15):Abstract 1005

  32. Valachis A, Polyzos NP, Patsopoulous NA, Georgoulias V, Mavroudis D, Mauri D (2010) Bevacizumab in metastatic breast cancer: a meta-analysis of randomised controlled trials. Breast Cancer Res Treat 122(1):1–7. doi:10.1007/s10549-009-0727-0

    Article  PubMed  CAS  Google Scholar 

  33. Gradishar WJ, Kaklamani V, Prasad TS, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M (2009) A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer. Cancer Res 69(24 Suppl 3):Abstract 44. doi:10.1158/0008-5472.SABCS-09-44

  34. Baselga J, Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H, Costa F, Getúlio Martins Segalla J, Pinczowski H, Ma Ciruelos E, Cabral Filho, S, Gómez P, Van Eyll B (2009) SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafinib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 69(Suppl 24):Abstract 45. doi:10.1158/0008-5472.SABCS-09-45

  35. Kaufman P, de Boer R, White S, Mainwaring P, Koczwara B, Urquhart LM, Ye Y, Sun Y, Adewoye H, Kotasek D (2009) Motesanib (AMG 706) in combination with paclitaxel or docetaxel: phase 1b study in patients with locally recurrent, unresectable or metastatic breast cancer. Eur J Cancer Suppl 7(2):269

    Article  Google Scholar 

  36. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiełło-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Baños A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR, TRIO 010 investigators (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12(4):369–376. doi:10.1016/S1470-2045(11)70037-7

    Google Scholar 

  37. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D (2011) Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 29(18):2459–2465. doi:10.1200/JCO.2010.31.2975

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank the patients and their families, as well as the network of investigators, research nurses, study coordinators, and operations staff who participated in this study, which was sponsored by Pfizer Inc. The authors also thank Daria Sanchez (ExecuPharm, Inc., King of Prussia, PA, USA) for her contribution as study manager. Medical writing support was provided by Wendy Sacks at ACUMED® (New York, NY) and was funded by Pfizer Inc.

Conflict of interest disclosures

E. C. Dees received research funding from Pfizer, Millennium Pharmaceuticals, Novartis, GlaxoSmithKline, and Genentech. S. Li and J. Paolini are employees of Pfizer. P. Healey, Z. Wang, M. J. Brickman, and K. A. Kern are or were employees of Pfizer and hold/held Pfizer stock. D. A. Yardley, S. D. Myers, and D. L. Citrin have no disclosures to report.

Author information

Author notes

  1. Zhixiao Wang

    Present address: Eisai Inc., Woodcliff Lake, NJ, USA

Authors and Affiliations

  1. The Sarah Cannon Research Institute and Tennessee Oncology, Suite 110, 250 25th Ave. North, Nashville, TN, 37203, USA

    Denise A. Yardley

  2. University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

    E. Claire Dees

  3. Baptist Hospital East, Louisville, KY, USA

    Stephen D. Myers

  4. Pfizer Oncology, Shanghai, China

    Sherry Li

  5. Pfizer Oncology, New London, CT, USA

    Paul Healey & Zhixiao Wang

  6. Pfizer Oncology, New York, NY, USA

    Marla J. Brickman

  7. Pfizer Oncology, Milan, Italy

    Jolanda Paolini

  8. Pfizer Oncology, La Jolla, CA, USA

    Kenneth A. Kern

  9. Cancer Treatment Centers of America, Midwestern Regional Medical Center, Zion, IL, USA

    Dennis L. Citrin

Authors
  1. Denise A. Yardley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Claire Dees
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen D. Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sherry Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul Healey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhixiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marla J. Brickman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jolanda Paolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kenneth A. Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dennis L. Citrin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denise A. Yardley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yardley, D.A., Dees, E.C., Myers, S.D. et al. Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Res Treat 136, 759–767 (2012). https://doi.org/10.1007/s10549-012-2285-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-2285-0

Keywords

Search

Navigation